Search bioRxiv⌕ Search

bioRxiv · 10.1101/2023.03.10.530869

Molecular cascades and cell-type specific signatures in ASD revealed by single cell genomics

Abstract

Understanding how genetic variation exerts its effects on the human brain in health and disease has been greatly informed by functional genomic characterization. Studies over the last decade have demonstrated robust evidence of convergent transcriptional and epigenetic profiles in post-mortem cerebral cortex from individuals with Autism Spectrum Disorder (ASD). Here, we perform deep single nuclear (sn) RNAseq to elucidate changes in cell composition, cellular transcriptomes and putative candidate drivers associated with ASD, which we corroborate using snATAC-seq and spatial profiling. We find changes in cell state composition representing transitions from homeostatic to reactive profiles in microglia and astrocytes, a pattern extending to oligodendrocytes and blood brain barrier cells. We identify profound changes in differential expression involving thousands of genes across neuronal and glial subtypes, of which a substantial portion can be accounted for by specific transcription factor networks that are significantly enriched in common and rare genetic risk for ASD. These data, which are available as part of the PsychENCODE consortium, provide robust causal anchors and resultant molecular phenotypes for understanding ASD changes in human brain. One-Sentence SummaryWe define the molecular cascades and cells disrupted in post-mortem brain in ASD by performing spatial, single nuclear RNA, and epigenetic profiling, and characterize, at unmatched resolution, the functional regulation of cell-type specific signatures underlying the molecular differences and physiology of ASD. Main TextPsychiatric disorders are defined primarily by behavioral and cognitive characteristics and are classically distinguished from neurological disorders by lacking the associated visible histological or macroscopic pathology observed in neurological conditions. However, a growing body of evidence based on genomic profiling reveals consistent molecular differences in brain tissue from specific neuropsychiatric conditions compared with brain tissue from neurotypical individuals (1-5). In Autism Spectrum Disorder (ASD) robust transcriptomic and epigenetic alterations in the cerebral cortex from patients have been documented over the last decade, delineating a reproducible pattern of molecular pathology (5-13). This robust molecular signature obtained primarily from transcriptomic profiling of bulk cortical tissue has identified convergent biological pathways in ASD brain, which is characterized by an upregulation of immune signaling genes, downregulation of specific neuronal markers, synaptic genes, and an attenuation of the typical patterns of gene expression associated with cortical regional identity (6-8,12-14). These genomic data represent an essential lens through which to understand the cellular and physiological changes occurring in the brains of autistic individuals and to describe potential causal mechanisms via their integration with genetic risk variants (1,4,5). However, small sample sizes in the case of single cell analysis (13), or profiling restricted to bulk tissue have limited biological insights as to the differences in laminar, circuit level, and cell-type specific pathways affected in ASD, as well as their underlying gene regulatory mechanisms. To address these limitations, we leveraged improvement in single cell analyses to profile the largest ASD cohort to date, consisting of 64 cases and controls. This resource, generated as a core component of the PsychENCODE consortium (1,2,4,5,8; http://www.psychencode.org), also enables us to characterize underlying candidate regulatory mechanisms and to connect causal drivers with the observed changes at a cell-type specific level in ASD, providing a deeper and more generalizable understanding of the cell types and biological mechanisms that underlie ASD. These data are available via PsychEncode portals for download (http://psychencode.synapse.org) and on the PsychSCREEN browser (in development, http://psychscreen.beta.wenglab.org).

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Wamsley, B., Bicks, L., Cheng, Y., Kawaguchi, R., Quintero, D., Grundman, J., Liu, J., Xiao, S., Hawken, N., Margolis, M., Mazariegos, S., Geschwind, D. H.. 2023-03-10. Molecular cascades and cell-type specific signatures in ASD revealed by single cell genomics. https://doi.org/10.1101/2023.03.10.530869

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

The Unreasonable Effectiveness of Cell Types in Describing Neuronal Physiological Features

Single-cell RNA sequencing (scRNA-seq) captures detailed gene expression profiles at scale, while patch-clamp recordings measure intrinsic neuronal electrophysiological properties. Modeling the relations between these two modalities remains a challenge. Here, we compare how well electrophysiological features can be predicted by traditional transcriptomic cell type classification, representations derived from a foundational model (scGPT) pretrained on large-scale scRNA-seq datasets, ion channel-coding genes, and highly variable genes. Using paired transcriptomic and electrophysiological patch-sequencing data from 495 human neurons from neurosurgical tissue, we find that cluster-level cell type representations consistently outperform highly variable gene selection, ion channel gene selection, and context-enriched scGPT embeddings. Notably, performance varies across model architectures and initializations, and the best results are obtained by combining the outputs of separate cell type and scGPT-based models. Together, these findings suggest that traditional discrete cellular classification is highly effective in predicting physiological features. For maximum performance it can be complemented by pretrained transformer models.

neuroscience↗

A nonlinear inhibition pathway underlying cortical responses to tuned holographic optogenetic perturbations

Optogenetics enables causal manipulation of cortical activity. Perturbation responses can be counterintuitive due to network interactions, making theory essential for predicting them. Existing approaches often rely on linear approximations, which fail for many biologically relevant perturbations. Here we develop a nonlinear theory of responses to holographic perturbations in cell-type-specific recurrent networks with structured connectivity. We fit a nonlinear model to mouse V1 data, which shows cotuned-ensemble suppression: perturbing spatially clustered neurons with similar preferred orientations yields markedly stronger short-range suppression than perturbing untuned ensembles. We show that cotuned-ensemble suppression arises from a feature-tuned, nonlinear inhibition pathway implicating somatostatin-positive (SST) interneurons. The theory predicts that cotuned ensembles suppress parvalbumin-positive (PV) neurons but facilitate SST neurons, and links the degree of cotuned-ensemble suppression or facilitation to the variance of the SST response. This framework identifies mechanisms by which nonlinear inhibition sculpts cortical dynamics and establishes a predictive basis for targeted optogenetic interventions.

neuroscience↗

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

The apolipoprotein E {varepsilon}4 (APOE {varepsilon}4) allele is the strongest genetic risk factor for late-onset Alzheimers disease (AD). However, the underlying molecular mechanisms remain unclear. This study included 1691 participants from the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), 1226 participants from the Accelerating Medicines Partnership - Alzheimers Disease (AMP-AD) Diverse Cohorts Study, and 735 participants from the Alzheimers Disease Neuroimaging Initiative (ADNI). To characterise APOE {varepsilon}4 molecular effects, we analysed proteomic data from plasma, cerebrospinal fluid (CSF), and induced pluripotent stem cell (iPSC)-derived astrocytes and neurons, as well as transcriptomic and proteomic data from multiple brain regions. The association of APOE {varepsilon}4 with AD neuropathology was also examined. APOE {varepsilon}4 carriers shared a plasma proteomic signature enriched for immune processes, irrespective of AD diagnosis. A machine learning classifier trained on this signature discriminated APOE {varepsilon}4 carriers from non-carriers in an independent cohort using CSF proteomics. APOE {varepsilon}4 carriage was associated with higher Braak stages and Consortium to Establish a Registry for Alzheimers Disease (CERAD) score. However, only limited APOE {varepsilon}4-associated transcriptomic and proteomic changes were observed in bulk brain tissue, with poor cross-layer concordance. Proteomic analyses of iPSC-derived astrocytes and neurons further revealed cell-type-specific APOE {varepsilon}4-associated changes. APOE {varepsilon}4 is associated with a consistent proteomic signature across plasma and CSF. Its molecular effects in the brain differ across cell types, brain regions and molecular layers. These findings support the need for cell-type-resolved multi-omic studies to elucidate how APOE {varepsilon}4 confers AD risk.

neuroscience↗